CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 7.6% – Here’s Why

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares dropped 7.6% during mid-day trading on Thursday . The stock traded as low as $1.2177 and last traded at $1.22. Approximately 9,423 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 28,199 shares. The stock had previously closed at $1.32.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CytoMed Therapeutics currently has an average rating of “Sell”.

CytoMed Therapeutics Stock Down 7.4%

The stock has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $1.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

CytoMed Therapeutics (NASDAQ:GDTC) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.06) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.